Immunogenomics of Metastatic Clear-Cell Renal Cell Carcinoma: Remarkable Response to Nivolumab in a Patient With a Pathogenic Germ Line BRCA1 Mutation

Clin Genitourin Cancer. 2019 Oct;17(5):e909-e912. doi: 10.1016/j.clgc.2019.06.013. Epub 2019 Jul 11.
No abstract available

Keywords: BRCA1 mutation; Immune checkpoint inhibitors; Predictive biomarkers; Renal cell carcinoma.

Publication types

  • Case Reports

MeSH terms

  • Aged
  • Antineoplastic Agents, Immunological / administration & dosage*
  • Antineoplastic Agents, Immunological / adverse effects
  • BRCA1 Protein / genetics*
  • Carcinoma, Renal Cell / drug therapy*
  • Carcinoma, Renal Cell / genetics
  • Germ-Line Mutation
  • Humans
  • Kidney Neoplasms / drug therapy*
  • Kidney Neoplasms / genetics
  • Male
  • Neoplasm Metastasis
  • Nivolumab / administration & dosage*
  • Nivolumab / adverse effects
  • Precision Medicine

Substances

  • Antineoplastic Agents, Immunological
  • BRCA1 Protein
  • BRCA1 protein, human
  • Nivolumab